Results 201 to 210 of about 198,891 (298)

Effectiveness of Saline Nasal Irrigation in the Treatment of Rhinosinusitis and Allergic Rhinitis in Pediatric Patients: A Systematic Review. [PDF]

open access: yesCureus
Salgado M   +9 more
europepmc   +1 more source

Protein Corona‐Coated Crystal Silica From Sandstorms Amplifies Allergic Rhinitis by Regulating Epithelial Integrity in Mice and Human Nasal Epithelia

open access: yes
Allergy, EarlyView.
Cuishuang Dong   +9 more
wiley   +1 more source

Factors for Success and Failure of Allergen Immunotherapy (AIT) Trial Design in the Light of Evidence‐Based Medicine: Current Aspects 2026

open access: yesAllergy, EarlyView.
ABSTRACT Allergen immunotherapy (AIT) has been acknowledged as the only disease‐modifying treatment for respiratory diseases since its introduction in 1911. Although the efficacy and safety have convincingly been established in numerous randomized clinical trials (RCTs), the AIT study results may vary substantially.
Roy Gerth van Wijk   +10 more
wiley   +1 more source

Human IgE Antibodies Recognize the Vicilin and Alpha‐Hairpinin Domains of Peanut Allergen Ara h 1

open access: yesAllergy, EarlyView.
The ɑ‐hairpinin of Ara h 1 contains a dominant epitope that is both frequently recognized and blocks a majority of the IgE against this domain. Including this region in tests may improve diagnosis of peanut allergy. The trimeric structure of the vicilin region explains the ability of Ara h 1 to induce anaphylaxis with a single antibody.
Taylor M. Cosey   +14 more
wiley   +1 more source

Asthma Remission From Childhood to Young Adulthood–A Population‐Based Cohort Study

open access: yesAllergy, EarlyView.
Among 257 participants with asthma at age 8 years, 39% achieved symptom‐based remission by age 24, 29% achieved clinical remission, and 18% achieved complete remission. Male sex increased the likelihood of symptom‐based remission, while food sensitization and overweight/obesity decreased the likelihood.
Lina Broström   +6 more
wiley   +1 more source

Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy

open access: yesAllergy, EarlyView.
We conducted a two stage SCIT trial with GNR‐127 containing a recombinant fusion protein consisting of Bet v 1 and Mal d 1‐derived peptides fused to PreS from HBV. Stage 1 identified two safe maximum tolerated doses (40 μg and 80 μg). In the following Stage 2, five preseasonal injections were well tolerated, induced dose‐dependent allergen‐specific IgG,
Musa R. Khaitov   +43 more
wiley   +1 more source

Home - About - Disclaimer - Privacy